Ovarian function and childbearing issues in breast cancer survivors
- PMID: 17926162
- DOI: 10.1080/09513590701582406
Ovarian function and childbearing issues in breast cancer survivors
Abstract
The increasing number of breast cancer survivors makes the issues of ovarian dysfunction and childbearing ability more and more relevant for the quality of life of these patients. The incidence of ovarian dysfunction is related to patient age, the specific agents used and the total dose administered, especially the dose of alkylating agents such as cyclophosphamide. Amenorrhea rates following combination chemotherapy consisting of cyclophosphamide + methotrexate + 5-flurouracil (CMF regimen) range from 21 to 71% in women aged 40 years and younger, and from 40 to 100% in older ones. In most series anthracycline-based adjuvant chemotherapy regimens appear to have a lower incidence of amenorrhea, which is probably due to the lower cumulative cyclophosphamide dose administered compared with that given in the CMF regimen. Few data are currently available regarding ovarian function in women treated with taxane-based chemotherapy. In a recent retrospective study on 191 patients, the amenorrhea rate was 64% for women who received doxorubicin + cyclophosphamide (AC regimen) followed by a taxane, compared with 55% (p = 0.05) for those treated with AC alone. Forty percent of women aged 40 years or younger resumed menstruation, whereas the amenorrhea was more likely to be irreversible in older women; however, the addition of a taxane did not change the reversibility rate. Ovarian reserve can be tested with serum assays of follicle-stimulating hormone, inhibin B, estradiol and anti-Müllerian hormone, as well as by ultrasound assessment of antral follicle count. A review of literature data failed to show that a subsequent pregnancy increases the risk of recurrence and death in breast cancer survivors, and some series have even detected longer survival for patients who get pregnant after breast cancer treatment. This apparent survival benefit, probably due to a selection bias called the 'healthy mother effect', suggests that breast cancer survivors who subsequently conceive are a self-selecting group of women with better prognosis. The little available information appears to show no increase in the incidence of prematurity, stillbirth or congenital malformations in their babies. In conclusion, future pregnancy is a viable option for a woman treated for early-stage breast cancer and does not appear to be detrimental to either the mother or her offspring.
Similar articles
-
The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.Am J Clin Oncol. 2007 Apr;30(2):126-32. doi: 10.1097/01.coc.0000251398.57630.4f. Am J Clin Oncol. 2007. PMID: 17414460
-
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.Fertil Steril. 2008 Nov;90(5):1635-9. doi: 10.1016/j.fertnstert.2007.09.048. Epub 2007 Dec 31. Fertil Steril. 2008. PMID: 18166178
-
Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.Cancer. 2006 Feb 1;106(3):514-23. doi: 10.1002/cncr.21646. Cancer. 2006. PMID: 16388519 Clinical Trial.
-
Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects.J Natl Cancer Inst Monogr. 1994;(16):125-9. J Natl Cancer Inst Monogr. 1994. PMID: 7999454 Review.
-
Measuring ovarian function in young cancer survivors.Minerva Endocrinol. 2010 Dec;35(4):259-70. Minerva Endocrinol. 2010. PMID: 21178920 Review.
Cited by
-
Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients.J Surg Oncol. 2017 Feb;115(2):116-121. doi: 10.1002/jso.24418. Epub 2016 Dec 14. J Surg Oncol. 2017. PMID: 27966219 Free PMC article.
-
Preservation of fertility in patients with cancer.N Engl J Med. 2009 Feb 26;360(9):902-11. doi: 10.1056/NEJMra0801454. N Engl J Med. 2009. PMID: 19246362 Free PMC article. Review. No abstract available.
-
Fertility preservation in women with breast cancer.Clin Obstet Gynecol. 2010 Dec;53(4):753-62. doi: 10.1097/GRF.0b013e3181f96e00. Clin Obstet Gynecol. 2010. PMID: 21048442 Free PMC article. Review.
-
Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.J Natl Cancer Inst. 2015 Aug 25;107(10):djv202. doi: 10.1093/jnci/djv202. Print 2015 Oct. J Natl Cancer Inst. 2015. PMID: 26307641 Free PMC article.
-
Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. JAMA Oncol. 2016. PMID: 26426573 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical